Inspire Medical Systems (INSP) 44th Annual J.P. Morgan Healthcare Conference summary

Financial performance and guidance

• Inspire V's full U.S. launch and strong adoption drove Q4 momentum, with 2025 revenue guidance at $912 million and 2026 guidance for 10%-11% growth, not including potential reimbursement increases; initial 2026 guidance also cited as $1.003–$1.013 billion.

• Five-year revenue CAGR exceeds 50%, with over 125,000 patients treated to date and more than 1,300 employees and 1,500 implanters supporting expansion.

• Margins are improving with Inspire V, and profitability is expected as revenue surpasses $1 billion; continued investment in R&D and commercial expansion is planned.

• Matt Osberg appointed as new CFO, starting January 2026, bringing broad experience to support the next growth phase.

• Reimbursement developments are ongoing, with positive steps noted but not yet included in financial outlook; current guidance and billing practices remain unchanged while alignment is sought.

Product innovation and clinical outcomes

• Inspire V features a single-port neurostimulator with an integrated accelerometer, reducing procedure time by 20% to 30-45 minutes and improving patient outcomes.

• Clinical data show improved respiratory sensing (87% inspiratory phase overlap), high responder rates (79%-80%), and strong therapy adherence (5.9–6.3 hours/night at six months).

• No serious device or intraoperative adverse events reported in recent studies; device reliability exceeds 97% at multiple years post-implant.

• Inspire VI, a software upgrade with auto sleep detection, and future features like posture-responsive therapy and auto start/pause are in development.

• New research shows statistically significant long-term cardiovascular benefits compared to CPAP and no treatment, supporting future labeling and reimbursement discussions.

Market expansion and operational strategy

• U.S. OSA market remains underpenetrated, with an estimated $10B opportunity and over 500,000 Inspire-eligible patients annually.

• Direct-to-consumer marketing, including new commercials and celebrity endorsements, is driving awareness and patient engagement.

• Growth strategy focuses on increasing utilization at existing centers, optimizing patient conversion, supporting ENT and sleep physicians, and international expansion.

• Over 1,300 employees and 1,500 implanters support ongoing expansion.

• International expansion and development of new indications, such as high BMI patients and dual-channel devices, are ongoing priorities.